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Overview—After presenting a definition of asthma, this
background paper turns to a review of the epidemiologi-
cal data that document the nature of the asthma epidemic
in the United States. Next, the paper discusses health
resources utilization linked to asthma and identifies the
subpopulations that are most vulnerable to asthma. A
brief assessment of the mechanics of asthma and the
challenges of diagnosing the disease follows. Then the
paper examines the possible causes of asthma and the
asthma epidemic, including indoor and outdoor environ-
mental factors, allergies and possible changes in the
immune system, and new theories about the relationship
of asthma to overall advances in health care and eco-
nomic development. After that, medical practice and
health care coverage issues are explored, including the
progress made in asthma management, possible deficien-
cies in physician practice, the state of patient information
about asthma, poverty-related barriers to asthma diagno-
sis and management, and the effects of health insurance
practices and the managed care revolution on asthma. An
examination of the economic implications of asthma and
possible cost avoidances linked to better asthma manage-
ment follows. The paper concludes with a discussion of
asthma and public health, including weaknesses in
current surveillance for the disease, and a review of the
plans of the Department of Health and Human Services
(DHHS) for addressing asthma.
In a front-page article in the New York Times last
fall, a reporter observed, “The rapid rise in asthma, in
this country and in developed nations around the world,
is one of the biggest mysteries in modern medicine.”1
Epidemiologic evidence suggests that she was not
exaggerating. Data from the Centers for Disease Con-
trol and Prevention (CDC) indicate that, between 1980
and 1994, the self-reported prevalence rate for asthma
in the United States jumped by 75 percent.2 Almost 6
percent of all Americans now have asthma, which has
become the most common chronic illness among
American children. While overall deaths from asthma
remain low—roughly 5,600 per year—asthma mortality
rates have more than doubled since the mid-1970s; this
is especially troubling given the consensus of profes-
sionals that asthma deaths are largely preventable.
While science has not yet conclusively identified the
root cause of asthma or discovered the means to limit
the current epidemic, the medical technology to control
individual cases of asthma exists. Indeed, the American
Medical Association (AMA) confidently declares, “The
characteristic symptoms of asthma . . . can be controlled.
Nearly every person with asthma can expect to become
free of symptoms.”3 However, of special concern from
a public policy perspective, available research indicates
that asthma is a particular problem for poor inner-city
children and for minority group members in general, as
evidenced by their notably higher rates of hospitaliza-
tion and use of emergency rooms for asthma treatment.
While the incidence of asthma in these populations is
not strikingly higher than in middle-class Anglo popula-
tions, asthma clearly affects Americans of color and
indigent urban residents more seriously. In part, this
differential impact seems to reflect their poor access to
medical care of acceptable quality, since medical
professionals concur that hospitalization and emergency
room treatment should not be part of routine care for the
vast majority of asthmatics.
Indeed, the evidence is strong that a significant
amount of medical resources are being expended
unnecessarily for urgent or emergent care for asthma
that could have been kept under control using readily
available therapies. To cite just one example, a recent
study indicates that asthma is the third leading cause of
preventable hospitalizations in the United States.4 To
put this in context, in absolute dollar terms, the total
annual costs of asthma in the United States were
estimated to be $11.3 billion in 1998, of which $7.5
billion were direct medical expenses.5
Given its implications for health care spending in the
United States, the asthma epidemic is receiving a great
deal of attention as a public policy issue from both the
public and the private sectors. Numerous federal agencies
—most notably the National Institutes of Health (NIH),
the CDC, and the Environmental Protection Agency
(EPA)—state and local public health departments,
individual practitioners and medical facilities, and health
plans are engaged in fighting asthma on a day-to-day
basis. Total Medicaid and Medicare expenditures for
asthma treatment are estimated to exceed $1 billion. The
federal government is investing more than $140 million
annually on asthma research. Yet critics have raised
questions about whether public dollars are being invested
wisely in the fight against asthma. While the nation has
some capacity to track asthma morbidity and mortality for
the population as a whole through surveys, it lacks data on
asthma prevalence rates specific to states and localities—
the front lines where most public health professionals
combat this epidemic.
BACKGROUND
In its authoritative Guidelines for the Diagnosis and
Treatment of Asthma, the National Heart, Lung, and
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Blood Institute (NHLBI) in the National Institutes of
Health (NIH) offered the following definition of the
disease:
Asthma is a chronic inflammatory disorder of the
airways. . . . In susceptible individuals, this inflamma-
tion causes recurrent episodes of wheezing, breath-
lessness, chest tightness, and coughing, particularly at
night or in the early morning. These episodes are
usually associated with widespread but variable
airflow obstruction that is often reversible either
spontaneously or with treatment. The inflammation
also causes an associated increase in the existing
bronchial hyperresponsiveness to a variety of stimuli.6
In its Family Guide to Asthma and Allergies, the
American Lung Association (ALA) points out a defin-
ing characteristic of asthma:
Much has been learned about asthma in recent years,
but nothing is more important than the observation
that asthma is a disease of airway inflammation. By
this physicians mean that people with asthma have
chronically inflamed airways that are ever prone to
become twitchy and constricted after exposure to an
asthma trigger. It is as if the airways of people with
asthma are lying in wait for trouble. They stay poised
at the edge of a cliff. . . . This means that asthma is
both a chronic and an episodic disease.7
There are two different forms of asthma. The first,
known as allergic or extrinsic asthma, is characterized by
attacks provoked by exposure to so-called asthma “trig-
gers,” such as pet dander, second-hand tobacco smoke,
dust mites, and mold spores. Typically, the onset of this
form of asthma occurs before the age 30; indeed, the vast
majority of childhood asthma is allergic. The second
form, nonallergic or intrinsic asthma, manifests itself
with the same symptoms as allergic asthma; however,
attacks of intrinsic asthma are not triggered by identifiable
allergens. While intrinsic asthma can begin at any age, the
onset typically occurs in adulthood.
THE ASTHMA EPIDEMIC—
A LOOK AT THE STATISTICS
As noted above, the CDC estimates that the preva-
lence of self-reported asthma among the general popu-
lation of the United States jumped by 75 percent
between 1980 and 1994. Figure 1 illustrates how the
prevalence escalated over this period. One of the
remarkable things about this escalation is that a substan-
tial increase occurred among all racial and ethnic
groups, both genders, and all age groups, with some
variations in the rate of increase, which will be dis-
cussed below.
The CDC estimates that asthma affected 14.6
million Americans in 1996. This translates into about
5.5 percent of the total population. (The comparable
figure for 1980 was about 3.0 percent.) In its recent
report, Attack Asthma, the Pew Commission on Envi-
ronmental Health observes that about half of the cases
of asthma in the United States today “are attributable to
the rising rates of asthma over the last 20 years.”8 In
other words, had the escalation in the prevalence of
asthma not taken place over the past two decades, only
half as many Americans would be experiencing asthma
today—in excess of 7 million fewer individuals.
Some might question whether the increased preva-
lence of asthma can be appropriately characterized as “an
epidemic.” One reason is that the term “epidemic” is
commonly understood to describe only infectious or
communicable diseases, such as tuberculosis or
HIV/AIDS. However, the term also encompasses non-
communicable diseases such as asthma. Action Against
Asthma, the strategic plan of the U.S. Department of
Health and Human Services (DHHS), notes, “The steady
rise in the prevalence of asthma constitutes an epidemic,
which by all indications is continuing.”9 In his often-cited
Dictionary of Epidemiology, John Last defines an epi-
demic as “the occurrence in a community or region of
Figure 1
Mean Rates of Self-Reported Asthma
U.S. Population, 1980–1994 
Source: Centers for Disease Control and Prevention, 1998.
Note: Rates are age-adjusted to the 1970 U.S. Population.
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 cases of an illness . . . clearly in excess of normal expec-
tancy.”10 Thus, the use of the term epidemic seems apt.
The asthma mortality rate has also undergone a
dramatic increase. From a low of 8.2 per million
Americans between 1975 and 1978, the rate of asthma
deaths more than doubled to 17.9 per million for the
period 1993 to 1995. As demonstrated in Figure 2,
especially noteworthy is the fact that this escalation
followed a dramatic decline of over 70 percent in
asthma mortality rates from
1960 to 1978. While the
number of asthma deaths in
the United States—5,637
in 1995—is relatively
small in relation to other
diseases, it translates into
about 15.4 deaths from
asthma every day. Further-
more, this trend clearly
seems to reflect deficien-
cies in the delivery of treat-
ment to asthma patients. A
securities analyst who spe-
cializes in health care ob-
served in the New York
Times last fall, “Right
now, asthma is the only
disease category we cover
where the death rate is ris-
ing. . . . That proves that
the disease is not being
treated properly.”11
Looking at the nation’s
public health goals for
asthma as articulated in
Healthy People 2000 and
Healthy People 2010, U.S.
Surgeon General David
Satcher observed, “Asthma
is one of the areas where
we are moving in the
wrong direction.”
Trends in Levels of
Health Resources Utilization
Both the asthma epidemic and the uncontrolled
nature of asthma in many cases are reflected in trends
in the levels of the utilization of hospital and other
health care resources for asthma patients. CDC data
indicate the following:
 From 1975 to 1995, estimated visits to physicians’
offices for asthma more than doubled, from 4.6
million to 10.4 million.12
 Between 1979-1980 and 1993-1994, the number of
hospitalizations for asthma increased from 386,000
to 466,000—or by almost 21 percent.13 
 The short-term trend data available for emergency
room (ER) visits indicate that, for the three-year
period 1992 to 1995, there were no major changes in
asthma-related ER visits. Nonetheless, asthma was the
tenth most common principal diagnosis in ER visits in
1996. (In the same year, asthma was the ninth most
frequent diagnosis in hospital outpatient departments.)
Figure 2
Asthma Death Rates, U.S. Population, 1960–1994
Source: Centers for Disease Control and Prevention.
Note: Rates are age-adjusted to the 1970 U.S. Population.
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Asthma and Vulnerable Subpopulations
CDC data clearly show that, for a variety of reasons,
a number of subpopulations of vulnerable Americans are
at high risk of developing asthma and/or of suffering
from asthma that is poorly controlled. Among these
groups are children, the elderly, racial and ethnic minori-
ties, the indigent, people living in urban areas, women,
and adults working in certain typically blue-collar jobs.
Asthma among Children. The escalation in the
prevalence of asthma among children over the past two
decades has been noticeably greater than that among
adults. For children under age five, the increase in
prevalence between 1980 and 1994 was 160 percent,
while the corresponding increase for the general
population was 75 percent. Although there are more
adult than child asthmatics, the prevalence of asthma
among children is higher. Overall, the rate of self-
reported asthma for children under 18 in 1995 was 7.5
percent, as contrasted with 5.7 percent for the general
population.
Asthma is the most common chronic disease among
children. Data from the AMA indicate that asthma
accounts for more hospital and ER visits for children
than any other reason. Of all age cadres, asthma hospi-
talization rates are highest for children under age five.
(In 1993-94, 49.7 per 10,000 children age four and
under were hospitalized for asthma, as contrasted with
18.1 per 10,000 for the population as a whole.)14
Asthma among the Elderly. Since there is no cure for
asthma, it is a disease that many people carry with them
into old age, at which time, for a number of reasons, its
control is especially difficult. For one thing, both
asthma and other diseases with asthma-like symptoms
are relatively common among older adults, increasing
the difficulty of diagnosis and proper treatment. Among
the conditions of old age which are commonly con-
founded with asthma are emphysema, bronchitis, and
chronic obstructive pulmonary disease. Because
polypharmacy—the simultaneous use of a number of
different prescription drugs—is more common among
the elderly, administering asthma medication to them
sometimes presents special difficulties related to
possible multiple drug interactions and contraindica-
tions. Asthma mortality rates are also highest among
the elderly, 89.8 per million in 1995, as contrasted with
17.9 per million for the general population.
Asthma, Race, and Ethnicity. In 1995, the rate of
self-reported asthma for African Americans was 6.7
percent, as contrasted with 5.6 percent for whites—not
a large difference. Yet deaths from asthma are between
two and six times more likely to occur to African
Americans and Hispanics than whites.15
Moreover, hospitalization rates for asthmatic African
Americans are almost three times higher than those for
whites with asthma. The use of ERs by minorities for
asthma care is also markedly higher. These utilization
statistics and those for death rates clearly point to less
well-controlled asthma among minorities.
Socioeconomic Status, Place of Residence, and
Asthma. Clearly, Americans living in poverty face a
complex set of variables that predispose them to poorly
controlled asthma. As the New York Times concisely
reported last fall,
The poor tend to have less access to regular medical
care, are less able to afford the medications they need
and are more likely to be around environmental
“triggers” that set off asthma attacks. Also, some
researchers have found, families already under great
stress are less able to cope with the complicated daily
regimen that asthma demands.16
There are also a number of indications that the
asthma epidemic has had a disproportionately heavy
impact on urban areas across the country—precisely the
areas with some of the greatest concentrations of
poverty. The Atlantic Monthly in May of this year
singled out one of the five boroughs of New York City
to report,17 “[In] the Bronx . . . rates of death from
[asthma] are three times as high . . . as they are in the
United States as a whole, and hospitalization rates are
almost five times as high. In some Bronx neighbor-
hoods, 20 percent of the children have asthma.” The
New York Times has referred to asthma as “the other
inner-city epidemic”—the first being HIV/AIDS.
Testimony before the Senate Public Health Subcommit-
tee last fall indicated, “More than 20 percent of U.S.
asthma deaths in one year occurred in New York City
and Chicago, even though these places had only 7
percent of Americans with asthma.”18 Dramatically
higher asthma death rates also characterize a number of
other urban areas across the country.
Among the possible reasons suggested for the
seemingly greater susceptibility to severe asthma of
Americans living in urban areas—especially poor inner-
city children—are greater exposure to outdoor air
pollutants (especially diesel fuel fumes), less time spent
outdoors (partly because of concerns over crime),
substandard housing (including poor ventilation,
dampness, and infestation by pests, particularly cock-
roaches), and greater reliance on hospitals for urgent
and emergent care. The associate commissioner of the
New York City Department of Health voiced concern
 6 
about a pervasive indifference to asthma control by
urban parents: “Our major concern was that people
were accepting a level of symptoms as being ‘normal.’”
Asthma and Gender. Asthma is more common among
boys than girls but becomes more common among
women than men as people age. The most recent self-
reported rates were 6.7 percent for women and 5.2
percent for men. Between 1980 and 1994, asthma in-
creased 92 percent among women but only 60 percent
among men. In the 1993 to 1995 period, asthma death
rates for women were slightly higher than those for men
(20.0 per million versus 15.1 per million). Hospitalization
rates for asthma are also higher among women than men
(20.0 versus 15.9 per 10,000 in 1993-94).
Occupational Asthma. Occupational asthma is charac-
terized by development of the disease because of expo-
sure to asthma sensitizers on the job. Since these sensitiz-
ers generally include various types of chemicals, indus-
trial and farm workers (particularly animal handlers) are
most likely to develop occupational asthma. The leading
work-related lung disease, occupational asthma accounts
for at least 21 percent of adult-onset asthma.
ASTHMA AS A DISEASE ENTITY
Asthma attacks—especially severe asthma attacks—
exact a heavy physical toll. Patients liken asthma
attacks to suffocating. Action Against Asthma features
two graphic descriptions of the experience:
 It’s a full body workout to take each breath. My
chest tightens up a lot and it either feels like I have
1,000 pounds of bricks on my chest or that someone
has their hands on my lungs and is squeezing with
all their might.
—An 18-year-old asthma sufferer
 It means that everyday events like soccer practice,
visits with friends who have cats, and even hay rides
require vigilance. Most of all, it means a cough is
not just a cough. It can be the first cough in a long
day and night punctuated every 10 seconds with
another sharp little cough.
—A young mother
Or, as the author of an article in May’s Atlantic Month-
ly commented, “What the condition lacks in lethality,
it more than makes up for in morbidity: it wears people
down, crushes their spirits, and threatens their liveli-
hoods.”
Noreen Clark, dean of the University of Michigan
School of Public Health and a prominent researcher in
asthma management, elaborates,
Patients and caretakers often become frustrated or
even angry because of the burdens that asthma im-
poses. Episodes of symptoms can be frightening
events. A study by our group of children’s asthma
attacks found that, during an attack, among low-
income mothers of children with asthma, 62 percent
felt frightened, 33 percent felt desperate, and 44
percent lacked the confidence to manage the attack.
Learning how to cope with fear and anxiety is an
important part of patient education.19
The Mechanics of Asthma
Physiologically, there are three ways in which
asthma constricts the airways during an asthma attack:
 Tightening of the muscles encircling the airways,
causing the airways to narrow—a phenomenon
called bronchospasm.
 Inflammation of the airways, because of the entrance
of fluid, blood cells, and irritating chemicals.
 Secretion of abnormal amounts of mucus, some-
times forming what is called a “mucus plug,” which
further restricts the passage of air.
As noted above, however, asthma is a chronic condi-
tion, and these acute manifestations of the disease are
only one element of what needs to be controlled in
effective asthma management.
There are gradations in the severity of asthma. These
relate to variations in (a) the severity of the chronic
disease, (b) the gravity of acute attacks, and (c) both
factors over time in an individual.
Diagnostic Challenges
Asthma is often difficult to diagnose. As a result, it
is frequently undiagnosed or misdiagnosed. The AMA
itself concedes, “Part of the problem lies with doctors
who do not keep up with developments in the field of
asthma; they may misread asthma symptoms or cling to
outdated or inaccurate information.”
But there are several inherent features of the disease
which make its diagnosis especially challenging. For one
thing, because the disease is both episodic and chronic,
diagnosis has a lot to do with timing of patient visits to
providers. Symptoms that may be quite evident when an
appointment was made may have subsided by the time a
practitioner examines a patient. Secondly, asthma is
frequently confused with other chronic disorders, such as
emphysema, bronchitis, heart disease, cystic fibrosis, and
chronic obstructive pulmonary disease. (There is one
basic difference, however—most of the airway obstruc-
tion caused by asthma can be reversed with medication.)
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Diagnosis of asthma in children under age six or
seven is fraught with particular difficulties. Such young
children often have special difficulty in following
directions about the use of equipment to measure lung
function, which requires them to exhale continuously at
their utmost capacity.
Finally, symptoms vary among patients. For exam-
ple, while wheezing is thought to be a general charac-
teristic of asthma, not all asthmatics wheeze. It is for
reasons like this that the Institute of Medicine (IOM)
concluded in its recent report on asthma and indoor air
exposures, “These findings raise the question of wheth-
er asthma is best thought of as a single disease entity,
a syndrome, or a final common manifestation of several
different disease processes.”20
POSSIBLE CAUSES OF ASTHMA AND
THE EPIDEMIC
There are at least three fundamental questions about
asthma and the public’s health. First, what causes
asthma? Second, what has caused the sharp escalation
in the prevalence of asthma? Third, what causes the
exacerbation of asthma symptoms in some people?
Unfortunately, there are no conclusive answers to either
of the first two questions; at best, there is suggestive
evidence. However, a great deal is known about what
exacerbates symptoms for some asthmatics, how those
symptoms can be controlled on a short-term basis, and
how asthma can be managed to prevent symptoms from
occurring over time.
With respect to the first question, the recent IOM
report concluded, “No single agent or factor has yet
been identified as a necessary or sufficient cause of
asthma.” Reflecting on the asthma epidemic, Satcher
commented, “Until you understand why you have an
increase, and you have documented it, it is very hard to
say you have a strategy that is going to make a differ-
ence.” The Pew Commission on Environmental Health
succinctly described the state of current science:
“While little is known about the factors that cause
asthma to develop (and even less about why prevalence
rates are going up), more is known about the factors
that cause exacerbation of asthma.”
Genetic Factors
For some time now, there has been widespread
speculation that genetic factors predispose some
individuals to asthma. But until very recently, discus-
sion of genetic influences on asthma have remained
largely conjectural. The IOM could at best conclude:
Most scientists believe that some individuals have a
prior underlying predisposition that permits the evolu-
tion of clinical asthma. The development of this predis-
position to asthma is dependent on a complex—and at
present poorly understood—combination of factors,
which are partially inherited and partially acquired later
in life. [However,] genetic influence . . . explains only
30-80 percent of the asthma risk. The remaining risk
seems to be related to environmental exposure.
As in so many areas of medicine, recent genetic
research holds promise for unlocking some of the
mysteries of asthma. In June 1999, the American
Journal of Public Health ran an editorial that reported,
Research focused on gene-environmental interactions
holds great promise in treating, managing, and ulti-
mately curing or preventing asthma. . . . Substantial
evidence exists for linking several chromosomal
regions with the development of asthma. . . . Many of
these areas contain genes whose functions may be
important to the development of airway inflammation
and asthma. Candidate genes . . . that may be impor-
tant to the pathophysiology of asthma are currently
being selected and examined.21
Environmental Factors
Despite the promising research on genetic causation of
asthma, there is consensus that the human genome could
not possibly have changed so radically over recent
decades as to explain the escalation of asthma morbidity
and mortality over that period. Since there is also general
agreement that some combination of genetic and environ-
mental factors eventuates in individual cases of asthma, a
number of observers have induced that some sort of
dramatic change in the indoor and/or outdoor environ-
ments lies at the root of the asthma epidemic.
Discussing the interrelationship of the immune system
and the environment in asthma, the AMA’s Essential
Guide to Asthma notes, “In asthma, the immune system
overreacts to elements in the environment.” Or, as the
Pew Environmental Health Commission expresses it,
“Genetics loads the gun [through its effects on the im-
mune system] . . . but environment pulls the trigger.”
After its exhaustive review of indoor air particulates
that might cause asthma, the IOM was compelled to
conclude, “We still do not know whether or to what
extent the reported increases in asthma can be attributed
to indoor exposures.”22 However, they reached three
strong positive conclusions, namely that there is suffi-
cient evidence of causal relationships between the
following:
 Exposure to house dust mite allergen and the devel-
opment of asthma in susceptible children.
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 Exposure to the allergens produced by cats, cock-
roaches, and house dust mites and exacerbation of
asthma in sensitized individuals.
 Environment tobacco smoke exposure and exacer-
bations of asthma in preschool-aged children.
There is limited evidence that exposure to some of
these factors may have increased over the past few
decades. For example, it is known that dust mites thrive
in indoor environments where air does not circulate.
Since the energy crisis of the 1970s, much residential
and office building construction has emphasized energy
conservation; in general, this means many buildings
without windows that open and/or a degree of insula-
tion that allows little air to circulate from the outside.
The AMA reports that the number of household pets is
on the rise. It is estimated that around 28 percent of
U.S. households have cats. The IOM report suggests
that one means of reducing risks of asthma exacerba-
tions is to remove cats from the homes of asthmatics.
There is also general evidence that people in advanced
industrial countries like the United States are spending
increasing time indoors, thus elevating the exposure of
susceptible individuals to those indoor agents that
might cause or exacerbate asthma.
No study has been done of the influence of outdoor air
quality on asthma that approximates the recent IOM study
in either scope or size. Many observers point to the fact
that air quality has been generally improving in recent
years as a reason that outdoor air pollution has probably
not contributed to the asthma epidemic. However, there
is some speculation that the increased usage of diesel fuel
may have contributed in some as-yet-to-be-determined
manner to the upsurge in asthma, especially in urban
areas.23 The NHLBI Guidelines for the Diagnosis and
Treatment of Asthma cautions about outdoor air pollution
as a cause of asthma exacerbations: “Increased air
pollution of respirable particulates, ozone, SO2 [sulfur
dioxide], and NO2 [nitrogen dioxide] have been reported
to precipitate asthma symptoms and increase emergency
department visits and hospitalizations for asthma.”
Asthma, Allergies, and the Immune System
Some asthma seems to be rooted in a malfunction-
ing immune system that overreacts to benign sub-
stances in the environment. A British discussion of the
asthma epidemic explains this phenomenon as follows:
We all have an immune system which is similar to a
defensive army, and this protects us from a huge
range of insults which our environment is inclined to
throw at us. These include bacteria, viruses, fungi,
yeasts, toxins, and allergens. The prime function of
the immune system is to distinguish between invaders
that may be harmful from those that are harmless.
Thus the immune system should act effectively
against microbes which may cause disease, but not
react against harmless items such as pollen, dust, dust
mite and food molecules.24
Yet it is precisely such “harmless items” that precipitate
asthma attacks among those with allergic asthma. In
general, allergic reactions are caused by changes or
abnormalities in the immune system—hence, the
medical subspecialty of allergy and immunology.
“Does Civilization Cause Asthma?”
Last May’s Atlantic Monthly article on asthma sums
up one recent school of thought about the asthma
epidemic:
A number of specialists . . . believe that modern life
may be responsible for the developed world’s asthma
rates—but in a very unexpected way. [They] believe .
modern hygiene practices and antibiotics . . . foreclose
the need for the young immune system to tackle
microbial and parasitic challenges. . . . This could
explain why children in the developing world, who
are repeatedly infected by bacteria and parasites, are
unlikely to contract asthma, whereas children in the
developed world, who are inoculated against infec-
tious diseases and frequently given antibiotics, are
contracting asthma in ever greater numbers.
Related variations of this theory are that children are
getting less healthy outdoor exercise—what might be
called the “couch potato corollary”—that the migration
of people from rural to urban areas has reduced their
exposure to organic factors that strengthen the immune
system, and that the widespread use of antibiotics, while
reducing the incidence of some infections, may be
contributing to the upsurge in asthma by retarding the
development of immune responses.
These theories are still highly conjectural at this stage.
Research is currently under way to test these hypotheses.25
MEDICAL PRACTICE AND HEALTH
CARE COVERAGE ISSUES
Nevertheless, despite the somewhat rudimentary stage
of the knowledge about the etiology of asthma and the
reasons for the current epidemic, there seems to be
consensus that all but the most severe cases of asthma can
be controlled and that almost every American with asthma
can enjoy a life largely free of symptoms. Yet there are
troublesome signs that the health care delivery system is
not keeping up with the epidemic, with attendant costs for
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both the national economy and for asthmatics themselves.
As Michael Rich, a pediatrician and child health re-
searcher at Harvard Medical School, remarked, “Billions
of dollars are being spent on [asthma], and we know a lot
about it, yet it’s getting worse, because we’re not asking
the right questions. The real question is, what stands in
the way of knowledge being translated into behavior?”26
Changing Science and Changing Therapies
There has been continued progress in developing
new asthma therapies—particularly pharmaceuticals
and devices—both making the control of asthma far
easier and reducing possible side effects. Unfortu-
nately, for a number of reasons, these therapies are not
being made available to all Americans with asthma.
One prominent researcher has likened the introduc-
tion of inhaled steroids for asthma to the discovery of
penicillin: “It turned treatment of asthma around com-
pletely.” Corticosteroids were first prescribed for
asthma patients in the 1960s and have proven very
effective in long-term asthma control. In the early
1980s, steroid inhalers were first introduced—a major
technological advance that targeted the lungs with the
drug, pumped less of it into the rest of the body, and
made daily use easier. The ALA declares, “Gone are
many of the side effects and cumbersome delivery
devices that complicated early asthma medications.”
In essence, corticosteroids suppress the activity of
immune system cells that release inflammatory chemi-
cals. It was not until the 1990s, however, that the
salience of inflammation as a factor in asthma attacks
was fully appreciated and the key role of cortico-
steroids in suppressing inflammation was completely
understood. Furthermore, a significant problem with
these drugs—which should not be confused with
anabolic steroids, the controversial drugs used by some
athletes—is their potential long-term side effects,
which include growth retardation (obviously a special
concern for pediatric patients), glaucoma, hypertension,
and osteoporosis.
Another important development has been the formula-
tion and issuance of national clinical practice guidelines
for asthma. In 1991, following a process of broad consul-
tation with experts in the field, the National Asthma
Education and Prevention Program (NAEPP) in the
NHLBI released its Guidelines for the Diagnosis and
Management of Asthma, which translate advances in the
scientific understanding of asthma—particularly the role
of chronic inflammation—into practical recommenda-
tions for controlling persistent asthma. An updated
edition of the guidelines was issued in 1997.
The NAEPP/NHLBI guidelines establish a number
of goals for asthma therapy:
 Preventing chronic and troublesome symptoms.
 Maintaining (near) “normal” pulmonary function.
 Maintaining normal activity levels (including exer-
cise and other physical activity).
 Preventing recurrent exacerbations of asthma and
minimizing the need for emergency department
visits or hospitalizations.
 Providing optimal pharmacotherapy with minimal or
no adverse effects.
 Meeting patients’ and families’ expectations of and
satisfaction with asthma care.
The guidelines proceed to offer health care professionals
detailed advice on how best to meet these goals. They
stress the importance of teaching asthma self-manage-
ment and prevention to patients and underscore the key
role of the partnership between patients and physicians.
The most recent edition of the guidelines is 146
pages long and quite detailed. To make their content
more accessible to practitioners, the NAEPP has issued
a more convenient Practical Guide for the Diagnosis
and Management of Asthma, which is published in a
larger print, bulleted format and totals only 52 pages.27
Deficient Medical Practice 
A number of sources speculate that primary care
physicians may not be as knowledgeable about asthma or
as up-to-date as they should be about advances in asthma
treatment. For example, the DHHS strategic plan, Action
Against Asthma, suggests, “Recent evidence indicates
that many health care providers do not follow the Guide-
lines for the diagnosis and treatment of asthma. Failure to
follow clinical guidelines stems in part from factors
related to knowledge, attitudes, and behavior.”
There is also general concern that many physicians
are addressing asthma on only a short-term, palliative
basis. That is, they are helping patients address asthma
attacks without getting at the underlying disease
through a course of long-term therapy. May’s Atlantic
Monthly asserts, “Some physicians are unaware that
asthma is a chronic disease requiring constant vigilance..
Many doctors seem to be prescribing drugs to curtail
asthma episodes rather than caring for the patient who
suffers them.”
Problems in primary care physician relationships
with their asthmatic patients seem to be underscored by
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statistics cited at the Senate Public Health Subcommit-
tee hearings on child health last fall:
More than 90 percent of children who present to the
emergency department with an asthma attack have a
primary care provider. Despite this, two-thirds go
directly to the emergency department when having
problems with their asthma and one-third rely on the
emergency department for all of their asthma medica-
tions.28
Furthermore, financial pressures may in some
instances be undercutting the ability of physicians to
invest the amount of time in patient education needed
by asthmatics. One physician observed,
When I first see a patient [who has asthma], I spend
an hour with him. . . . I can do this because I’m an
academic physician who gets paid by the year, not by
the patient. A general pediatrician working under
managed care has to see four to six patients an
hour—he doesn’t have the time to talk about diet,
exercise, the kid’s environment. And that’s why these
kids keep ending up in the ER.
Finally, there is speculation that some physicians
may not be as up-to-date on current asthma medications
as they should. The AMA Essential Guide to Asthma
emphasizes,
Different medications with serious side effects are
introduced each year. New studies document asthma
triggers and evaluate drug reactions. Your doctor needs
up-to-date expertise to integrate this information into
the long-term program that works best for you.
Confused, Uninformed, or Noncompliant
Patients
A number of observers emphasize the difficulty
patients experience in adapting to an asthma treatment
regimen. For severe asthma, some have likened the
complexity of therapies to those for treating HIV/
AIDS. Yet even treatment for routine asthma can be
burdensome. A prominent physician-researcher ob-
served to a New York Times reporter,
Asthma takes a lot of work. . . . You have to take daily
medication, at fixed intervals, and sometimes in
response to changes in symptoms. And inhalers are
fundamentally unpleasant devices. Many patients
have at least two inhalers that have to be taken at
different times. The more you ask patients to do, the
less they do.
He went on to express concern that many patients and
parents do not get appropriate guidance on how to treat
the disease: “They’re just handed a prescription and told
to use it, without an in-depth explanation of the
disease.”29
Noreen Clark underscores the crucial role of patient
judgment in the management of asthma:
Asthma management requires a high degree of judg-
ment on the part of the patient. There is no absolute
recipe for successful control. Sometimes asthma
symptoms are predictable and sometimes they are not.
A patient needs to be highly self-regulating, that is,
have the ability to observe, judge, and act on the basis
of subtle changes in symptoms or peak flow [respira-
tory] values or functional status. It may be that devel-
oping skills of self-regulation is more important than
learning asthma facts.
Patients who experience symptoms more than twice a
week generally need two different types of drugs, a “long-
term control medication” that suppresses inflammation
over a lengthy period (for example, a corticosteroid) as
well as a “quick-relief medication” that opens airways and
facilitates breathing when an asthma attack occurs.
Getting patients to adhere to this treatment regimen—
especially indigent patients who lack adequate third-party
coverage—has proven difficult. Many patients tend to
rely solely on the “quick-relief” drug.
The Washington Post reports that fewer than 20
percent of Americans with asthma use anti-inflammatorie-
s, as contrasted with 65 percent of asthmatics in Europe.
In general, physician failure to prescribe the medication
seems to be at the root of the problem. However, patient
nonadherence to prescriptions may also play a role.
According to a physician at the Institute for Asthma and
Allergy at the Washington Hospital Center,
Corticosteroids don’t make you feel better immedi-
ately. The emergency medicine makes you feel better
but doesn’t address the underlying problem. . . . [As a
result,] the most important medicine is the one people
feel they don’t need, so they stop taking it and get into
trouble.30
Action Against Asthma declares without qualification,
“Effective medical management and patient education
reduces the use of emergency services and improves
quality of life.” Thus, the bottom line issue appears to
be in part how to promote effective patient education.
Poverty-Related Barriers to Diagnosis and
Management of Asthma
At its hearing last fall, the Senate Public Health
Subcommittee was informed about a basic complex of
obstacles to patient compliance: “Poverty, single parent
families, and multiple caregivers are major barriers to
adherence with complex chronic treatment regimens.”
A physician who practices in a low-income section of
Washington, D.C., expressed the same thought some
what differently: “To manage asthma well you need a
11 
functioning medical system, society, and family.” A
Washington Post reporter observes, “Good care is a
cumbersome, labor-intensive, costly process—which is
why so many financially hard-pressed families end up
doing little or nothing until a crisis hits and they must
rush their kids to the emergency room.” Even such
structural barriers as deficient or inconvenient public
transportation systems contribute to impeding access by
poor families to needed ongoing asthma care.
But the problem seems tied to something more basic
than any of these poverty-related variables. Access to
medical care of acceptable quality is a basic problem
for indigent patients. Irwin Redlener, M.D., president
of the Children’s Hospital at Montefiore Medical
Center in the Bronx points out,
If you cannot at the end of the day provide the medi-
cal care that you have educated people about, you
have only completed half the bargain and you end up
with some very frustrated families. . . . We have
patients coming to us who have learned from the
public education campaign who say to us, ‘But we
need a doctor.’
The end results are evident in one study of asthma care
in New York City, which found that there were 223 ER
visits for asthma for every 10,000 Spanish Harlem
residents, while certain wealthy lower Manhattan
districts had no ER visits for this problem.31
Health Insurance Practices and the
Managed Care Revolution
This year, the Administration for Healthcare Research
and Quality (AHRQ) issued a study indicating that in
1996 about 78,000 hospital admissions for asthma among
children were covered by Medicaid, 68,000 admissions
were paid for by private insurance, and 8,000 children
without insurance were admitted for asthma. Hospital
admissions for asthma were proportionately lower for
children with private insurance than for either children
with Medicaid or uninsured children—2.1 percent, 3.2
percent, and 2.6 percent, respectively.32
Even those who have private insurance coverage face
certain barriers to care for their asthma, including restric-
tions on the number or length of preventive or follow-up
visits, limits on reimbursements, and lack of coverage for
patient education or case management. The obstacles
faced by those covered by managed care may be even
more challenging, insofar as they relate to gatekeeping
requirements and limits on provider panels.
For routine cases of asthma, most primary physicians
should be able to treat patients appropriately. (As noted
above, this supposes that they are both knowledgeable
and not confronted by productivity constraints that
prevent them from spending adequate time with asthmatic
patients.) However, for more severe cases of asthma,
treatment by experienced providers—or in some cases,
specialists such as pulmonologists or allergists—is
necessary. Insofar as managed care physician panels lack
sufficient numbers of such experienced providers or
specialists, or if managed care gatekeeping impedes the
access of severely asthmatic patients to such providers,
managed care poses an obstacle to acceptable quality
asthma care. Similarly, some managed care plans may
steer patients with serious asthma away from tertiary care
hospitals because of perceived higher costs.
On the other hand, managed care holds significant
promise for asthma treatment. Along with diabetes,
asthma has been singled out by a number of managed
care organizations (MCOs) for special disease manage-
ment initiatives. This is partly because of the dividends
to health plans’ case management initiatives from even
relatively short-term interventions to prevent asthma
attacks from escalating to the point of a need for
emergency care. By offering asthmatics a “medical
home” with continuity of care, managed care can also
make an important contribution to controlling asthma.
Furthermore, the National Committee for Quality
Assurance (NCQA), an accrediting organization whose
proclaimed mission is “to evaluate and report on the
quality of the nation’s managed care organizations,” has
incorporated an asthma measure in its most recent
edition of HEDIS (the Health Plan Employer Data and
Information Set), its performance measurement tool for
MCOs. This new asthma indicator, “Appropriate
Medications for People with Asthma,” measures the
percentage of MCO members with asthma who receive
medications recommended as primary therapy for long-
term control of the disease, including inhaled cortico-
steroids. (NCQA explains that addition of another
proposed HEDIS asthma measure, “Emergency Room




Testimony presented to the Senate Public Health
Subcommittee last fall indicates:
More than 80 percent of the total direct costs of
asthma result from the 20 percent of the asthma
patients who have significantly greater morbidity
measures and who are readily identifiable as the
 12 
highest users of hospital-based asthma services. In
1990, nearly half of all asthma health care costs were
due to severe illness consequences such as hospital-
izations and emergency room visits.33
This evidence suggests the possible merits of targeting
asthma cost-containment efforts on the minority of
high-cost patients.
Direct and Indirect Costs
An analysis done of medical expenditures for asthma
in 1990 indicates that the estimated $3.64 billion in direct
costs were broken down approximately as follows:34
 Inpatient hospitalization, 43 percent.
 Prescription medications, 30 percent.
 Physician-related services, 14 percent.
 ER visits, 8 percent.
 Outpatient hospital visits, 5 percent.
This evidence suggests that asthma cost containment
efforts ought to focus on inpatient hospitalization,
prescription drugs, and ER visits, assuming that physi-
cian services and hospital outpatient care are for the
most part necessary and efficiently delivered.
Of the estimated $11.3 billion total costs of asthma
in 1998, $3.8 billion, or roughly 34 percent, were cal-
culated to be indirect costs. These indirect costs in-
cluded lost work time, missed school days, and limita-
tions on daily activity. Healthy People 2010 indicates
that 19.5 percent of people with asthma in the period
1994 to 1996 had activity limitations. It also points out
that asthma ranks as the fourth most common chronic
condition in the United States.
It is estimated that children with asthma miss three
times as many school days as their classmates without the
disease. A school director from East Harlem character-
izes asthma as “an assault on the children” and describes
the consequences for their education: “The time that is
lost from the classroom, you can’t recover that time. . . .
With kids that are coming in with several strikes against
them to begin with, this just complicates matters.”
Potential Cost Avoidances
No one appears to have developed an estimate of
how much might be saved if asthma in the United
States were truly under control—if the disease were
being optimally diagnosed and managed in keeping
with available guidelines and technology. However,
using the percentages cited above, it is at least concep-
tually possible to estimate that eliminating unnecessary
emergency room visits and inpatient hospitalizations is
likely to save billions of dollars. Obviously, there would
be additional savings in such indirect costs as reduced
productivity and lost school and work days, as well as
added years of life for those who would otherwise die
as a result of asthma.
One of the physicians testifying before the Senate
child health hearing last fall pointed out,
Approximately 50 percent of the economic impact [of
asthma] is associated with emergency department
visits, hospitalization, and death—in other words,
expenditures related to asthma exacerbations rather
than the management of chronic stable asthma.35
The AMA Essential Guide to Asthma notes, “The key
to living a healthy life with asthma appears to be
preventing emergencies; a comprehensive medical plan
along with monitoring of the person’s condition are the
keys to stopping asthma attacks before they start.” The
same observation might be made about the centrality of
preventing emergencies to avoiding unnecessary costs
of asthma. The interventions needed to prevent asthma
emergencies are spelled out in the NAEPP’s asthma
guidelines.
Here again, effective patient education is a linchpin
of successful asthma management. Clark points out,
Outcomes achieved through well-conceptualized and
well-delivered patient education have been shown to
include reductions in school absences and use of
emergency department and hospital services, increases
in patient self-efficacy, and use of asthma-manage-
ment strategies, less frequent wheezing, and improved
academic performance.
ASTHMA AND PUBLIC HEALTH IN
THE UNITED STATES
There are a number of different reasons why asthma
warrants the attention of health policymakers at all
levels of government. Among these are the overall costs
of treating the disease; the effects on citizens’ lives,
education, and incomes; the promise of available
therapies and patient and provider education for reduc-
ing these costs; and the practices of third-party payers
that may result in inefficient and/or inappropriate
asthma coverage limitations.
Surveillance for Asthma
One of many impediments to developing a coherent
national asthma strategy is the highly-decentralized
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nature of the nation’s public health system. The loci of
most of the nation’s public health activity related to
asthma and many other major diseases are state and
local (primarily county) governments. As might be
expected, given such a large element of state and local
control, the capacity of the public health system to
confront a challenge like the asthma epidemic is
extremely uneven. Local health departments vary from
storefront operations with a staff of only a few profes-
sionals in rural areas to large, complex bureaucracies
like those in New York and Los Angeles.
A related problem is that surveillance is largely a
matter of state volition. Because epidemics like asthma
are no respecters of state boundaries, this yields a
public health dilemma—states with aggressive surveil-
lance systems for asthma and other diseases may find
the effectiveness of their efforts compromised by
neighboring states that choose not to engage in surveil-
lance. This problem is especially likely to affect multi-
state metropolitan areas.
It is therefore not surprising that one of the major
factors standing in the way of a national asthma strategy
is the lack of a strong surveillance system to track
changes in the prevalence of asthma at the subnational
level. While a number of other diseases are reported
through state and local health departments to the CDC,
which tracks trends in these diseases and reports them
back to state and local governments, no such system
exists for asthma. A 1996 CDC survey showed that 27
states had no ongoing asthma monitoring or tracking
systems.
Satcher has stated, “In public health, we can’t do
anything without surveillance. . . . That’s where public
health begins.” Indeed, one of the basic principles of
public health is that “to measure is to get it done.” If a
public health agency does not know the specifics of
what it is tracking, it cannot measure the progress it has
made. To employ a mixed metaphor used by Health-
Track, a Georgetown University environmental health
project, in its recent report on asthma surveillance, “In
our fight against asthma, we have given public health
professionals not radar, but a blindfold, and then asked
them to perform like a circus knife-thrower.”36
Most indications are that the costs of putting a
national asthma surveillance system in place would be
more than offset by the savings resulting from better
control of the disease. Among the very real impedi-
ments to implementing such a system, however, are the
demands it would place on physicians, hospitals, and
other health care providers to report asthma cases.
DHHS Strategic Plans and Asthma
Asthma is a major focal point for Healthy People
2010, the federal government’s strategic public health
plan for the next ten years. The plan has eight goals
related to asthma, among them sizable reductions in the
rates of asthma-related deaths, hospitalizations, and ER
visits. Somewhat more nebulous are goals related to
reducing the rate of activity limitations among people
with asthma and increasing the ratio of people with
asthma who receive patient education. Labeled “develop-
mental” are goals addressing reduction in the number of
missed school or work days, increasing the proportion of
people with asthma who receive care in accordance with
the NAEPP guidelines, and establishing a surveillance
system for tracking asthma in at least 15 states, which
would include data on asthma deaths, rates of illness,
levels of disability, and the impact of occupational and
environmental factors on asthma. (The goals designated
“developmental” are contingent on the development of
data sources.)
Healthy People 2000 also had three asthma-related
objectives: (a) a reduction in asthma hospitalizations
from 188 per 100,000 in 1987 to no more than 160 per
100,000 in 2000, (b) a reduction in activity limitations
among people with asthma from 19.4 percent in 1986-
1988 to 10 percent, and (c) a general increase in the
proportion of people with chronic and disabling condi-
tions who receive patient education from a baseline of
9 percent in 1991 to 50 percent in 2000. Limited
progress was reported in increased patient education
rates, while the rates of hospitalization and limitations
on activity both increased—in part, perhaps, because of
the increased prevalence of asthma.
Action Against Asthma, the DHHS strategic plan
issued in May 2000, identifies four relatively broad
“priorities for investment”:
 Determine the causes of asthma and develop inter-
ventions to prevent its onset.
 Reduce the burden of asthma for people living with
the disease.
 Eliminate the disproportionate burden of asthma in
minority populations and those living in poverty.
 Track the disease and assess the effectiveness of
asthma programs.
These sweeping, rather all-encompassing priorities
from Action Against Asthma seem to complement the
more specific, quantified goals set forth in Healthy
People 2000 and Healthy People 2010.
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